Rapport Therapeutics (RAPP) Cash from Investing Activities (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Cash from Investing Activities data on record, last reported at $37.9 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 80.41% to $37.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$170.6 million, a 59.13% decrease, with the full-year FY2025 number at -$187.5 million, down 10.19% from a year prior.
- Cash from Investing Activities reached $37.9 million in Q1 2026 per RAPP's latest filing, up from -$174.3 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for RAPP hit a ceiling of $37.9 million in Q1 2026 and a floor of -$174.3 million in Q4 2025.
- A 4-year average of -$36.2 million and a median of -$41.9 million in 2024 define the central range for Cash from Investing Activities.
- Peak YoY movement for Cash from Investing Activities: crashed 101901.92% in 2024, then skyrocketed 150.16% in 2025.
- Tracing RAPP's Cash from Investing Activities over 4 years: stood at -$78.7 million in 2023, then soared by 140.59% to $31.9 million in 2024, then plummeted by 645.96% to -$174.3 million in 2025, then surged by 121.76% to $37.9 million in 2026.
- Business Quant data shows Cash from Investing Activities for RAPP at $37.9 million in Q1 2026, -$174.3 million in Q4 2025, and -$56.8 million in Q3 2025.